Given the interest in HCV in these parts, I’m surprised no one has commented on the comments in #msg-50187183. Is MRK pulling a fast one on the investment community by touting a Boceprevir NDA submission in 2010 while internally planning for an FDA decision to be delayed until 2012 or 2013? (This is a serious question, not a rhetorical one.)
Market Data 
Markets 
AI
